Yiming Biologics Partners with U.S.-based Cellinfinity BIO to Advance Clinical Translation and Industrialization of In Vivo CAR-T Therapies

　　【Pharmaceutical Network Industry DynamicsIn recent years, in vivo CAR-T has come into the industry's view, and many pharmaceutical companies are actively promoting the clinical transformation and industrialization process of in vivo CAR-T therapy.
 

IMMUNE CELL and Cellinfinity BIO, a U.S.-based biotechnology company, recently announced a formal strategic partnership. The two parties will focus on the in-depth collaboration of pipelines under research, such as CIB-301 and CIB-350, in the fields of hematological malignancies and solid tumor treatments, jointly promoting the clinical translation and industrialization process of in vivo CAR-T therapy.
 

Among them, CIB-301 is an innovative research project for solid tumor treatment, utilizing an in vivo CAR vector and incorporating a self-developed fully human, low off-target risk CAR scFv. CIB-350 is an innovative therapeutic project targeting hematological tumors and autoimmune diseases, employing an in vivo CAR vector and featuring a novel integrated bispecific CAR targeting structure capable of simultaneously targeting two distinct B-cell antigens. Currently, the CMC development, pharmacokinetics/pharmacodynamics, and toxicology studies related to these two products are underway.
 

IMMUNE CELL representatives stated that as global cell therapy moves from personalization to scale, innovative technologies are continuously breaking through the bottlenecks of clinical translation. The strategic cooperation with Cellinfinity BIO on in vivo CAR-T projects such as CIB-301 and CIB-350 is an important practice of this concept.
 

In January this year, CSPC PHARMACEUTICAL GROUP LIMITED announced new progress in in vivo CAR-T therapy. The company's self-developed "SYS6055 Injection" obtained the clinical trial implied permission from the National Medical Products Administration (NMPA), with the acceptance number: CXSL2500947. This is China's clinically approved in vivo CAR-T therapy, indicated for relapsed/refractory aggressive B-cell lymphoma. In addition, domestic pharmaceutical companies such as Everest Medicines and CARsgen Therapeutics are also accelerating their layout. Other data shows that there are currently more than a hundred companies in China deploying in vivo CAR-T.
 

Moreover, the in-vivo CAR-T field is witnessing active financing. Data shows that by 2025, the total amount of in-vivo CAR-T related financing in China has exceeded 2 billion RMB. For instance, DeliNova Therapeutics, a company that has been committed to in-vivo CAR-T since its establishment, completed seed and angel rounds of financing totaling nearly 60 million RMB just six months after its inception. DeliNova Therapeutics' in-vivo CAR-T product targeting CD19, GI-001, is about to initiate patient enrollment for its first clinical trial (IIT), which will serve as a validation of the company's core technology system.
 

In vivo CAR-T, which uses gene delivery technology to directly "modify" T cells within the patient’s body, eliminates the need for ex vivo separation, expansion, and reinfusion. This compresses the treatment process from weeks to just a few days, with costs also expected to drop significantly. In addition to Chinese pharmaceutical companies, overseas firms are also accelerating their efforts in this space. Data shows that globally, there are over 20 in vivo CAR-T projects in preclinical or early clinical stages, targeting CD19 and BCMA. Moreover, the applications extend beyond hematologic tumors to solid tumors and autoimmune diseases. For instance, in March 2025, AstraZeneca made a bold move by spending 7 billion yuan to acquire EsoBiotec, an in vivo cell therapy company, further igniting industry enthusiasm. Additionally, overseas biotechs such as Capstan, Umoja, and Interius are also actively advancing their pipelines.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.